Zobrazeno 1 - 10
of 531
pro vyhledávání: '"Schlenzig D"'
Publikováno v:
In Protein Expression and Purification December 2015 116:75-81
Autor:
Tan K; Department of Drug Design and Target Validation MWT, Fraunhofer Institute for Cell Therapy and Immunology IZI, Biocenter, Halle (Saale), Germany., Jäger C; Vivoryon Therapeutics N.V., Halle (Saale), Germany., Geissler S; Department of Drug Design and Target Validation MWT, Fraunhofer Institute for Cell Therapy and Immunology IZI, Biocenter, Halle (Saale), Germany., Schlenzig D; Department of Drug Design and Target Validation MWT, Fraunhofer Institute for Cell Therapy and Immunology IZI, Biocenter, Halle (Saale), Germany., Buchholz M; Department of Drug Design and Target Validation MWT, Fraunhofer Institute for Cell Therapy and Immunology IZI, Biocenter, Halle (Saale), Germany., Ramsbeck D; Department of Drug Design and Target Validation MWT, Fraunhofer Institute for Cell Therapy and Immunology IZI, Biocenter, Halle (Saale), Germany.
Publikováno v:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2165648.
Autor:
Linnert, M., Fritz, C., Jäger, C., Schlenzig, D., Ramsbeck, D., Kleinschmidt, M., Wermann, M., Demuth, H.-U., Parthier, C., Schilling, S.
The astacin protease Meprin v represents an emerging target for drug development due to its potential involvement in disorders such as acute and chronic kidney injury and fibrosis. Here, we elaborate on the structural basis of inhibition by a specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::198e6ec3a8f116da17d8efa81a3e82ae
https://publica.fraunhofer.de/handle/publica/268639
https://publica.fraunhofer.de/handle/publica/268639
Autor:
Bayly-Jones C; Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, Australia.; ARC Centre of Excellence in Advanced Molecular Imaging, Monash University, Melbourne, VIC, Australia., Lupton CJ; Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, Australia.; ARC Centre of Excellence in Advanced Molecular Imaging, Monash University, Melbourne, VIC, Australia., Fritz C; Department for Drug Design and Target Validation (IZI-MWT), Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany., Venugopal H; Ramaciotti Centre for Cryo-Electron Microscopy, Monash University, Clayton, 3800, VIC, Australia., Ramsbeck D; Department for Drug Design and Target Validation (IZI-MWT), Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany., Wermann M; Department for Drug Design and Target Validation (IZI-MWT), Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany., Jäger C; Vivoryon Therapeutics N. V., Halle, Germany., de Marco A; Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, Australia.; ARC Centre of Excellence in Advanced Molecular Imaging, Monash University, Melbourne, VIC, Australia., Schilling S; Department for Drug Design and Target Validation (IZI-MWT), Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany.; Hochschule Anhalt, University of Applied Sciences, Köthen, Germany., Schlenzig D; Department for Drug Design and Target Validation (IZI-MWT), Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany. dagmar.schlenzig@izi.fraunhofer.de., Whisstock JC; Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, Australia. james.whisstock@monash.edu.; ARC Centre of Excellence in Advanced Molecular Imaging, Monash University, Melbourne, VIC, Australia. james.whisstock@monash.edu.; EMBL Australia, Monash University, Melbourne, VIC, 3800, Australia. james.whisstock@monash.edu.; ACRF Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research, Australian National University, Canberra, ACT, 2601, Australia. james.whisstock@monash.edu.
Publikováno v:
Nature communications [Nat Commun] 2022 Oct 19; Vol. 13 (1), pp. 6178. Date of Electronic Publication: 2022 Oct 19.
Recombinant expression and purification of amyloid peptides represents a common basis for investigating the molecular mechanisms of amyloid formation and toxicity. However, the isolation of the recombinant peptides is hampered by inefficient separati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::aed6d68b5e267e6eb43b7b81696e82a0
https://publica.fraunhofer.de/handle/publica/249274
https://publica.fraunhofer.de/handle/publica/249274
The astacin proteases meprin a and beta are emerging drug targets for treatment of disorders such as kidney failure, fibrosis or inflammatory bowel disease. However, there are only few inhibitors of both proteases reported to date. Starting from NNGH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::27cf3fa6f94e5227dff05330dce360a8
https://publica.fraunhofer.de/handle/publica/251812
https://publica.fraunhofer.de/handle/publica/251812
Autor:
Linnert M; Fraunhofer Institute for Cell Therapy and Immunology, Department of Drug Design and Target Validation, Weinbergweg 22, 06120 Halle (Saale), Germany., Fritz C; Fraunhofer Institute for Cell Therapy and Immunology, Department of Drug Design and Target Validation, Weinbergweg 22, 06120 Halle (Saale), Germany., Jäger C; Vivoryon Therapeutics N. V., Weinbergweg 22, 06120 Halle (Saale), Germany., Schlenzig D; Fraunhofer Institute for Cell Therapy and Immunology, Department of Drug Design and Target Validation, Weinbergweg 22, 06120 Halle (Saale), Germany., Ramsbeck D; Fraunhofer Institute for Cell Therapy and Immunology, Department of Drug Design and Target Validation, Weinbergweg 22, 06120 Halle (Saale), Germany., Kleinschmidt M; Fraunhofer Institute for Cell Therapy and Immunology, Department of Drug Design and Target Validation, Weinbergweg 22, 06120 Halle (Saale), Germany., Wermann M; Fraunhofer Institute for Cell Therapy and Immunology, Department of Drug Design and Target Validation, Weinbergweg 22, 06120 Halle (Saale), Germany., Demuth HU; Fraunhofer Institute for Cell Therapy and Immunology, Department of Drug Design and Target Validation, Weinbergweg 22, 06120 Halle (Saale), Germany.; Faculty of Applied Biosciences and Process Engineering, Anhalt University of Applied Sciences, Bernburger Street 55, 06366 Köthen, Germany., Parthier C; Institute of Biochemistry and Biotechnology, Charles-Tanford-Proteinzentrum, Martin-Luther-University Halle-Wittenberg, Kurt-Mothes-Street 3a, 06120 Halle (Saale), Germany., Schilling S; Fraunhofer Institute for Cell Therapy and Immunology, Department of Drug Design and Target Validation, Weinbergweg 22, 06120 Halle (Saale), Germany.; Faculty of Applied Biosciences and Process Engineering, Anhalt University of Applied Sciences, Bernburger Street 55, 06366 Köthen, Germany.
Publikováno v:
International journal of molecular sciences [Int J Mol Sci] 2021 May 26; Vol. 22 (11). Date of Electronic Publication: 2021 May 26.
Autor:
Kolobova, Elizaveta1,2 (AUTHOR) kolobova98@yandex.ru, Petrushanko, Irina1 (AUTHOR) irina-pva@mail.ru, Mitkevich, Vladimir1 (AUTHOR) mitkevich@gmail.com, Makarov, Alexander A1 (AUTHOR) aamakarov@eimb.ru, Grigorova, Irina L1,2 (AUTHOR) grig76@gmail.com
Publikováno v:
Cells (2073-4409). Oct2024, Vol. 13 Issue 19, p1624. 22p.
Autor:
Tan K; Department of Drug Design and Target Validation MWT, Fraunhofer Institute for Cell Therapy and Immunology IZI, Biocenter, Weinbergweg 22, 06120, Halle (Saale), Germany., Jäger C; Department of Drug Design and Target Validation MWT, Fraunhofer Institute for Cell Therapy and Immunology IZI, Biocenter, Weinbergweg 22, 06120, Halle (Saale), Germany.; present address: Vivoryon Therapeutics N.V., Weinbergweg 22, 06120, Halle (Saale), Germany., Körschgen H; Institute of Molecular Physiology, Cell and Matrix Biology, Johannes Gutenberg-University Mainz, Johann-Joachim-Becher-Weg 7, 55128, Mainz, Germany., Geissler S; Department of Drug Design and Target Validation MWT, Fraunhofer Institute for Cell Therapy and Immunology IZI, Biocenter, Weinbergweg 22, 06120, Halle (Saale), Germany., Schlenzig D; Department of Drug Design and Target Validation MWT, Fraunhofer Institute for Cell Therapy and Immunology IZI, Biocenter, Weinbergweg 22, 06120, Halle (Saale), Germany., Buchholz M; Department of Drug Design and Target Validation MWT, Fraunhofer Institute for Cell Therapy and Immunology IZI, Biocenter, Weinbergweg 22, 06120, Halle (Saale), Germany., Stöcker W; Institute of Molecular Physiology, Cell and Matrix Biology, Johannes Gutenberg-University Mainz, Johann-Joachim-Becher-Weg 7, 55128, Mainz, Germany., Ramsbeck D; Department of Drug Design and Target Validation MWT, Fraunhofer Institute for Cell Therapy and Immunology IZI, Biocenter, Weinbergweg 22, 06120, Halle (Saale), Germany.
Publikováno v:
ChemMedChem [ChemMedChem] 2021 Mar 18; Vol. 16 (6), pp. 976-988. Date of Electronic Publication: 2020 Dec 23.
Autor:
Wagner, L., Wolf, R., Zeitschel, U., Rossner, S., Petersén, A., Leavitt, B.R., Kästner, F., Rothermundt, M., Gärtner, U.-T., Gündel, D., Schlenzig, D., Frerker, N., Schade, J., Manhart, S., Rahfeld, J.-U., Demuth, H.-U., Hörsten, S. von
The bioactivity of neuropeptide Y (NPY) is either N-terminally modulated with respect to receptor selectivity by dipeptidyl peptidase 4 (DP4)-like enzymes or proteolytic degraded by neprilysin or meprins, thereby abrogating signal transduction. Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::f9242d9a8112e0d4edea7ee303b615f7
https://publica.fraunhofer.de/handle/publica/243370
https://publica.fraunhofer.de/handle/publica/243370